Dr. Patrick Forde is the Director of the Thoracic Cancer Clinical Research Program and Associate Professor of Oncology at Johns Hopkins Medicine. He is currently an associate member of the Bloomberg~Kimmel Institute for Cancer Immunotherapy and has acted as a lead developer of a clinical-translational research program focused on the immuno-oncology of upper aerodigestive malignancies. Dr. Forde is extremely active in research, often running multiple clinical trials at one time. His research focuses on the role of neoadjuvant anti-PD-1 therapy and other similar immunotherapies in earlier stage lung cancer and mesothelioma.

Dr. Forde has also been involved in leading several international clinical trials of new immunotherapy approaches for lung cancer and mesothelioma that are currently active in Europe, Asia and North America, while also serving as the principal investigator for the thoracic cancer immunobiology biospecimen repository at Johns Hopkins Medicine. His work has been published in numerous publications, as well as receiving awards for his achievements in cancer research.

Main Specialty: Thoracic Oncology

Other Interests & Specialties: Mesothelioma, lung cancer, thoracic cancer, upper aerodigestive malignancies, internal medicine and cancer immunotherapy.

Certifications, Awards & Accolades: Member of the American Association for Cancer Research, member of the American Society of Clinical Oncology, member of the International Association for the Study of Lung Cancer, Fellowship Award from the International Association for the Study of Lung Cancer (IASLC), Career Development Award from the LUNGevity Lung Cancer Foundation, Paul Carbone MD Fellowship Award, Director’s Teaching Award in Clinical Science, AACR-SU2C Phillip A. Sharp Innovation in Collaboration Award, ESMO Travel Award

Education & Experience:

  • Medical Degree from Royal College of Surgeons in Ireland
  • Residency in Internal Medicine at Royal College of Physicians Ireland
  • Residency in Medical Oncology from Mater Misericordiae University Hospital
  • Residency in Medical Oncology from Beaumont Hospital
  • Fellowship in Medical Oncology from Cork University Hospital
  • Fellowship in Medical Oncology from St James’s Hospital
  • Fellowship in Oncology from Johns Hopkins University School of Medicine

Use of Immune Checkpoint Inhibitors in MesotheliomaCurrent Treatment Options in Oncology. February 2019;20(2):18. doi: 10.1007/s11864-019-0613-x

Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint ImmunotherapyJournal of Thoracic Oncology. March 2019;14(3):494-502. doi: 10.1016/j.jtho.2018.11.016

Electrochemotherapy with cisplatin increases survival and induces immunogenic responses in murine models of lung cancer and colorectal cancerCancer Letter. February 2019;442:475-482. doi: 10.1016/j.canlet.2018.11.015

Mesothelioma Clinical Trials by Patrick Forde, MD

Dr. Forde is associated with the following clinical trials:

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

Conditions: Mesothelioma

Last Updated: July 5, 2019

Status: Not yet recruiting

Photo of Dr. Patrick Forde

Get Help Contacting Dr. Patrick Forde

    Privacy policy: All information is secure and will never be released



    Mesothelioma Treatment Guide

    Please fill in the form to request our FREE Mesothelioma Treatment Guide.
    It will be sent to you within 24 hours.

    Free Mesothelioma Treatment Guide

      Privacy policy: All information is secure and will never be released